When.com Web Search

  1. Ads

    related to: new medication for severe eczema side effects
    • What Is Eczema?

      Find Important Facts & Information

      To Understand Atopic Dermatitis.

    • Atopic Dermatitis

      Learn About Causes, Symptoms,

      & An Oral Treatment Option.

Search results

  1. Results From The WOW.Com Content Network
  2. EBGLYSS for eczema: What to know about the newly FDA ... - AOL

    www.aol.com/ebglyss-eczema-know-newly-fda...

    A newly approved drug for the treatment of atopic dermatitis could make a big difference to people with moderate-to-severe eczema. Image credit: Sascha Lotz/picture alliance via Getty Images.

  3. Lebrikizumab - Wikipedia

    en.wikipedia.org/wiki/Lebrikizumab

    Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin’s lymphoma had been performed when Genentech acquired Tanox in 2007.

  4. Abrocitinib - Wikipedia

    en.wikipedia.org/wiki/Abrocitinib

    In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...

  5. Dupilumab - Wikipedia

    en.wikipedia.org/wiki/Dupilumab

    Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis, [9] prurigo nodularis [10] and ...

  6. Eczema Drug Developer Nektar Gains Analyst Confidence With ...

    www.aol.com/eczema-drug-developer-nektar-gains...

    November 4, 2024 at 3:44 PM. Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential. Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ: NKTR ...

  7. Mepolizumab - Wikipedia

    en.wikipedia.org/wiki/Mepolizumab

    Mepolizumab. Mepolizumab, sold under the brand name Nucala by GlaxoSmithKline, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome (HES). [5] It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system ...

  1. Ads

    related to: new medication for severe eczema side effects